A cursory glance at the ongoing trials registered in the website ClinicalTrials.gov reveals that there are several phase I and phase II clinical trials presently underway with 177Lu-PSMA in advanced castration-resistant prostate cancer patients. This evidence concerns the gene FOLH1 and prostate cancer.